RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+0.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.56B
AUM Growth
+$7.56B
(-3.8%)
Cap. Flow
+$595M
Cap. Flow
% of AUM
7.87%
Top 10 Holdings %
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$130M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
$115M |
| 3 |
Arcellx
ACLX
|
$88.5M |
| 4 |
Avidity Biosciences
RNA
|
$86.5M |
| 5 |
Biogen
BIIB
|
$56M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$91.9M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$54.6M |
| 3 |
Cytek Biosciences
CTKB
|
$45.7M |
| 4 |
VXRT
Vaxart
VXRT
|
$20M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$19.4M |
Sector Composition
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $2.91M | 0.04% |
333,333
| – | – |
|
77
Unicycive Therapeutics
UNCY
$75.8M
| $1.32M | 0.02% |
263,220
-83,849
| -24% | -$420K |
|
78
Scilex Holding
SCLX
$131M
| $504K | 0.01% |
+7,462
| New | +$504K |
|
79
Black Diamond Therapeutics
BDTX
$164M
| – | – |
-3,525,754
| Closed | -$17.9M |
|
|
CMPS
80
Compass Pathways
CMPS
$452M
| – | – |
-791,359
| Closed | -$6.58M |
|
|
81
Cytek Biosciences
CTKB
$501M
| – | – |
-6,809,404
| Closed | -$45.7M |
|
82
CureVac
CVAC
$1.21B
| – | – |
-1,965,707
| Closed | -$5.96M |
|
|
83
EyePoint Pharmaceuticals
EYPT
$827M
| – | – |
-938,591
| Closed | -$19.4M |
|
|
IGMS
84
DELISTED
IGM Biosciences
IGMS
| – | – |
-937,500
| Closed | -$9.05M |
|
|
85
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-204,500
| Closed | -$54.6M |
|
|
VXRT
86
DELISTED
Vaxart
VXRT
| – | – |
-15,384,615
| Closed | -$20M |
|
|
INBX
87
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-2,629,837
| Closed | -$91.9M |
|